• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis.倍他斯汀治疗过敏性结膜炎相关眼部瘙痒的批判性评价
Clin Ophthalmol. 2011;5:201-7. doi: 10.2147/OPTH.S8665. Epub 2011 Feb 15.
2
Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.贝他斯汀倍他司汀滴眼液治疗过敏性结膜炎眼部症状的长期疗效。
J Ocul Pharmacol Ther. 2011 Aug;27(4):385-93. doi: 10.1089/jop.2011.0005. Epub 2011 Jun 7.
3
Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.苯海拉明倍他司汀贝他斯汀滴眼液 1.0%和 1.5%在过敏性结膜炎中的起效时间和作用持续时间：一项成人和儿童的 III 期、单中心、前瞻性、随机、双盲、安慰剂对照、结膜变应原挑战评估的研究。
Clin Ther. 2009 Sep;31(9):1908-21. doi: 10.1016/j.clinthera.2009.09.001.
4
Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference.通过患者偏好评估1.5%倍他斯汀滴眼液与0.2%盐酸奥洛他定滴眼液的比较疗效。
Clin Ophthalmol. 2012;6:1731-8. doi: 10.2147/OPTH.S35431. Epub 2012 Oct 29.
5
Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.贝他斯汀倍他甲磺酸盐滴眼液 1.0%和 1.5%治疗过敏性结膜炎的多中心临床评价。
Am J Ophthalmol. 2010 Jul;150(1):122-127.e5. doi: 10.1016/j.ajo.2010.02.007. Epub 2010 May 20.
6
Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.贝他斯汀倍他司汀眼用制剂 1.5%治疗过敏性结膜炎相关眼痒的整合 III 期临床试验。
Allergy Asthma Proc. 2012 May-Jun;33(3):265-74. doi: 10.2500/aap.2012.33.3570.
7
Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis.比较分析盐酸奥洛他定 0.2%、盐酸氮䓬斯汀 0.25%和贝他斯汀 1.5%治疗过敏性结膜炎的安全性和有效性。
Indian J Ophthalmol. 2021 Feb;69(2):257-261. doi: 10.4103/ijo.IJO_2083_20.
8
Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial.贝他斯汀滴眼液 1.5%治疗季节性过敏性结膜炎的疗效：一项随机、安慰剂对照、自然暴露、临床试验。
Allergy Asthma Proc. 2013 May-Jun;34(3):247-54. doi: 10.2500/aap.2013.34.3671.
9
Bepotastine besilate for the treatment of pruritus.贝他斯汀倍他司汀治疗瘙痒。
Expert Opin Pharmacother. 2013 Dec;14(18):2553-69. doi: 10.1517/14656566.2013.849242. Epub 2013 Nov 5.
10
Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis.1.5%苄普地尔眼药水用于缓解过敏性结膜炎患者的鼻部症状。
J Asthma Allergy. 2018 Mar 23;11:29-39. doi: 10.2147/JAA.S160687. eCollection 2018.

引用本文的文献

1
Ophthalmology in Persian medicine.波斯医学中的眼科
J Med Ethics Hist Med. 2014 Dec 3;7:19. eCollection 2014.

本文引用的文献

1
Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.贝他斯汀倍他甲磺酸盐滴眼液 1.0%和 1.5%治疗过敏性结膜炎的多中心临床评价。
Am J Ophthalmol. 2010 Jul;150(1):122-127.e5. doi: 10.1016/j.ajo.2010.02.007. Epub 2010 May 20.
2
Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.贝他斯汀倍他司汀，一种高度选择性的组胺 H(1)受体拮抗剂，可抑制体外和体内变应性结膜炎模型中的血管高通透性和嗜酸性粒细胞募集。
Exp Eye Res. 2010 Jul;91(1):85-91. doi: 10.1016/j.exer.2010.04.006. Epub 2010 Apr 20.
3
Bepotastine (bepreve)--an ophthalmic H1-antihistamine.贝波司汀（Bepreve）——一种眼科用H1抗组胺药。
Med Lett Drugs Ther. 2010 Feb 8;52(1331):11-2.
4
New drugs: asenapine, iloperidone, and bepotastine besilate.新药：阿塞那平、伊潘立酮和贝波司他丁。
J Am Pharm Assoc (2003). 2010 Jan-Feb;50(1):107-10. doi: 10.1331/JAPhA.2010.10505.
5
Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.苯海拉明倍他司汀贝他斯汀滴眼液 1.0%和 1.5%在过敏性结膜炎中的起效时间和作用持续时间：一项成人和儿童的 III 期、单中心、前瞻性、随机、双盲、安慰剂对照、结膜变应原挑战评估的研究。
Clin Ther. 2009 Sep;31(9):1908-21. doi: 10.1016/j.clinthera.2009.09.001.
6
Multiple H1-antihistamine-induced urticaria.多种H1抗组胺药诱发的荨麻疹
J Dermatol. 2009 Apr;36(4):224-7. doi: 10.1111/j.1346-8138.2009.00627.x.
7
Downmodulatory effects of the antihistaminic drug bepotastine on cytokine/chemokine production and CD54 expression in human keratinocytes.抗组胺药贝波司汀对人角质形成细胞中细胞因子/趋化因子产生及CD54表达的下调作用
Skin Pharmacol Physiol. 2009;22(1):45-8. doi: 10.1159/000183924. Epub 2008 Dec 17.
8
Evaluation of efficacy and sedative profiles of H(1) antihistamines by large-scale surveillance using the visual analogue scale (VAS).使用视觉模拟量表（VAS）通过大规模监测评估H(1)抗组胺药的疗效和镇静情况。
Allergol Int. 2008 Sep;57(3):257-63. doi: 10.2332/allergolint.O-07-525. Epub 2008 Jul 1.
9
Ocular allergy treatment.眼部过敏治疗
Immunol Allergy Clin North Am. 2008 Feb;28(1):189-224, vii. doi: 10.1016/j.iac.2007.12.001.
10
Allergic conjunctivitis.过敏性结膜炎
Immunol Allergy Clin North Am. 2008 Feb;28(1):43-58, vi. doi: 10.1016/j.iac.2007.12.005.

倍他斯汀治疗过敏性结膜炎相关眼部瘙痒的批判性评价

Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis.

作者信息

Wingard Jeremy B, Mah Francis S

机构信息

UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

出版信息

Clin Ophthalmol. 2011;5:201-7. doi: 10.2147/OPTH.S8665. Epub 2011 Feb 15.

DOI:10.2147/OPTH.S8665
PMID:21386912
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3046989/
Abstract

Bepotastine besilate 1.5% solution is an H(1)-antihistamine recently approved by the Food and Drug Administration for the topical treatment of ocular itching associated with allergic conjunctivitis. Several clinical studies have demonstrated its safety as well as its efficacy versus placebo. This review finds that bepotastine besilate 1.5% solution is a suitable alternative to other agents within the class of H(1)-antihistamines, but there are no clinical trial data to suggest that it holds any specific advantages over other agents.

摘要

1.5%苄普地尔溶液是一种H(1)抗组胺药，最近获美国食品药品监督管理局批准用于局部治疗与过敏性结膜炎相关的眼部瘙痒。多项临床研究已证明其安全性以及与安慰剂相比的疗效。本综述发现，1.5%苄普地尔溶液是H(1)抗组胺药类别中其他药物的合适替代品，但尚无临床试验数据表明它比其他药物具有任何特定优势。